@juliemovesyou's HRT advice gets most things right

What did @juliemovesyou actually say?

Julie Renee Hereward, a self-described 20-year fitness professional, made a straightforward argument: after 40, the reason your body stops responding the way it used to is physiology, not laziness. She pointed to estrogen shifts, testosterone drops, slower recovery, and cortisol changes as the culprits. She said she has "considered HRT" but hasn't started, and framed the conversation around muscle mass, bone density, metabolism, longevity, and mood. She also warned viewers not to buy hormones from unregulated sources.

Crucially, she is not claiming HRT is right for everyone. She is not prescribing. She is telling people to educate themselves and talk to real professionals. That framing matters when evaluating what she actually said versus what viewers might take away.

Does the science back this up?

Mostly, yes. The physiological claims she made are well-supported in the literature, even if she simplified some of them.

On testosterone: both men and women experience testosterone decline with age. In women, testosterone drops significantly through perimenopause, and this is associated with reduced lean mass and libido (Davis et al., 2015, The Lancet Diabetes and Endocrinology). On estrogen: the sharp drop during perimenopause accelerates muscle loss and impairs muscle protein synthesis. Research by Sipila et al. (2020, Journal of Cachexia, Sarcopenia and Muscle) found that estrogen plays a direct role in maintaining skeletal muscle function in women over 40.

On cortisol: older adults do show blunted recovery and altered hypothalamic-pituitary-adrenal axis responses to exercise stress, which extends perceived effort and soreness (Traustadottir et al., 2005, Journal of Clinical Endocrinology and Metabolism). Her claim that "recovery is slower" is accurate and has a documented hormonal basis.

On bone density: estrogen's role in bone remodeling is one of the most replicated findings in endocrinology. The Women's Health Initiative data showed HRT reduces fracture risk, though with tradeoffs worth discussing with a physician.

What did they get wrong (or right)?

She got the core physiology right. The hormonal shifts she described are real. Credit where it is due: she framed HRT as a personal consideration, not a universal prescription, and she told people to consult actual professionals. That is more responsible than most fitness influencers operating in this space.

Where she simplified: testosterone does not just "drop" after 40 in women in a single clean event. The decline is gradual, starts in the late 20s, and varies enormously between individuals (Davison and Davis, 2003, Best Practice and Research Clinical Endocrinology and Metabolism). Framing it as a post-40 cliff is a bit of an oversimplification, though not wrong in spirit.

She also uses "HRT" loosely without distinguishing between testosterone therapy, estrogen therapy, progesterone therapy, or combination protocols. These are different interventions with different evidence bases and risk profiles. A viewer walking away thinking "HRT" is one thing could end up confused in a clinical conversation. That is a real gap in her messaging, even if unintentional.

Her gym-bro warning, "Never EVER buy peptides or hormones from the bro slangin' them at the gym," is correct and worth amplifying. Unregulated hormone sources carry serious risks including contamination, misdosed compounds, and legal exposure.

What should you actually know?

If you are a woman over 40 noticing changes in body composition, recovery, or energy, Julie is right that physiology is a legitimate explanation worth investigating. You are not imagining it, and it is not simply a discipline problem.

However, the decision to pursue hormone therapy is not simple. The evidence on hormone therapy in perimenopausal and postmenopausal women is genuinely complex. The Women's Health Initiative initially scared clinicians away from HRT in the early 2000s due to cardiovascular and breast cancer signals. Subsequent reanalysis by Manson et al. (2013, JAMA Internal Medicine) showed that risk profiles differ significantly based on age of initiation, type of hormone, and route of administration. Transdermal estrogen, for example, carries a different clot risk profile than oral estrogen.

Testosterone therapy for women specifically remains an area where clinical guidance is still evolving. The Global Consensus Position Statement (Baber et al., 2019, Climacteric) supports testosterone use for hypoactive sexual desire disorder in women, but data on body composition and athletic performance outcomes is thinner than what circulates in fitness communities.

Talk to a board-certified endocrinologist or ob-gyn with specific hormone experience. Get baseline labs. Understand what you are treating and why.